Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Pollera

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Approved drugs for unlabeled uses: national health cost containment denies access to state-of-the-art cancer therapies in ItalyC F Pollera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabineC F Pollera
Oncology|January 1, 1989
Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide aloneC F Pollera, F Calabresi
International Journal of Clinical Pharmacology Research|January 1, 1996
Gemcitabine: safety profile unaffected by starting doseC Martin, C F Pollera
Cancer|September 1, 1989
Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic modelC F Pollera, D Giannarelli
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Cisplatin-induced peripheral neurotoxicity: relationship to dose intensityC F Pollera, A Pietrangeli, D Giannarelli
Medical and Pediatric Oncology|October 26, 1999
Nephroblastoma in the adultS De Marco, C F Pollera, F Cognetti
Lancet (London, England)|August 25, 1984
Sudden death after acute dystonic reaction to high-dose metoclopramideC F Pollera, F Cognetli, M Nardi, et al.
Investigational New Drugs|January 1, 1994
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I studyC F Pollera, A Ceribelli, M Crecco, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1991
Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over studyC F Pollera, M Nardi, P Marolla, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Approved drugs for unlabeled uses: national health cost containment denies access to state-of-the-art cancer therapies in ItalyC F Pollera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabineC F Pollera
Oncology|January 1, 1989
Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide aloneC F Pollera, F Calabresi
International Journal of Clinical Pharmacology Research|January 1, 1996
Gemcitabine: safety profile unaffected by starting doseC Martin, C F Pollera
Cancer|September 1, 1989
Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic modelC F Pollera, D Giannarelli
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Cisplatin-induced peripheral neurotoxicity: relationship to dose intensityC F Pollera, A Pietrangeli, D Giannarelli
Medical and Pediatric Oncology|October 26, 1999
Nephroblastoma in the adultS De Marco, C F Pollera, F Cognetti
Lancet (London, England)|August 25, 1984
Sudden death after acute dystonic reaction to high-dose metoclopramideC F Pollera, F Cognetli, M Nardi, et al.
Investigational New Drugs|January 1, 1994
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I studyC F Pollera, A Ceribelli, M Crecco, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1991
Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over studyC F Pollera, M Nardi, P Marolla, et al.
Pageof 3